DESIGN AND DEVELOPMENT OF NANOSTRUCTURED LIPID CARRIER CONTAINING TRIAMCINOLONE ACETONIDE
Objective: The aim of present study was to prepare nanostructured lipid carriers (NLCs) based Triamcinolone acetonide (TA).
Methods: Nanostructured lipid carriers (NLCs) consisted of solid lipid and liquid lipid are a new type of lipid nanoparticles, prepared by using solvent diffusion and high pressure homogenization methods, which offer the advantage of improved drug loading capacity and release properties. Glyceryl monostearate selected as the solid lipid, capmul MCM C8 as the liquid lipid, polyvinyl Alcohol (PVA) as the surfactant. NLCs dispersion was characterized by particle size analysis, zeta potential, scanning electron microscopy (SEM), differential scanning calorimetry, and an in vitro release study.
Results: Optimized NLCs loaded with TA were exhibited spherical shape with particle size 286.1 nm, polydispersity index 0.317, zeta potential-21.9 mV and entrapment efficiency 86.19% respectively. The result of differential scanning calorimetry (DSC) showed that drug was dispersed in NLCs in a crystalline state. In vitro release studies revealed that drug release of optimized batch was 8.34 % and 88.84% at 1h and 8h respectively. The release kinetics of the optimized NLCs best fitted the peppas-korsmeyer model. Furthermore, morphological investigations by SEM showed that optimized batch exhibit a spherical shape and a smooth surface.
Conclusion: Thus, the results indicated that successfully prepared TA-loaded NLCs and could potentially be exploited as a carrier with improved drug loading capacity and sustained drug release. The present results demonstrated that these systems could be a promising platform for inflammatory diseases, in particular for psoriasis topical therapy.
2. Carmona Ribeiro AM. Biomimetic nanoparticles: preparation, characterization and biomedical applications. Int J Nanomed 2010;5:249-59.
3. Sahu AR, Bothara SB. Formulation and evaluation of selfmicroemulsifying drug delivery system of curcumin for enhanced solubility and dissolution. Asian J Pharm Clin Res 2015;29:893-913.
4. Kovacs SZ, Berko E, Csany I. Development of nanostructured lipid carriers containing salicyclic acid for dermal use based on the quality by design method. Eur J Pharm Sci 2016:4-5. Doi:10.1016/j.ejps.2016.12.020
5. Muller RH. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Delivery 2002;54:131-55.
6. Pardeike J. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009;366:170-84.
7. Wiedersberg S, Leopold CS, Guy RH. Bioavailability and bioequivalence of topical glucocorticoids. Eur J Pharm Biopharm 2008;68:453-66.
8. Brazzini B, Pimpinelli N. New and established topical corticosteroids in dermatology. Am J Clin Dermatol 2002;3:47-58.
9. Heugtena AJ, Boerb W, Vriesb WS. Development and validation of a stability-indicating HPLC-UV method for the determination of triamcinolone acetonide and its degradation products in an ointment formulation. J Pharm Biomed Anal 2018;149:265-70.
10. Patwekar SL, Pedewad SR. Development and evaluation of nanostructured lipid carriers based gel of isotretinoin. J Particul Sci Technol 2017;36:286-90.
11. Muller RH, Ruh D, Runge S, Schulze Forster K, Mehnert W. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. J Pharm Res Int 1997;14:458-62.
12. Panda R, Kuotsu K. Fabrication, characterization, and in vitro evaluation of Pegylated glyceride labrasol nanostructured lipid carrier composit of methotrexate: the pathway to effective cancer therapy. Asian J Pharm Clin Res 2019;12:29-37.
13. Knudsen NO, Jorgensen L, Hansen J, Vermehren C, Frokjaer S. Targeting of liposome associated calcipotriol to the skin: effect of liposomal membrane fluidity and skin barrier integrity. Int J Pharm 2011;416:478-85.
14. Zhang YT, Shen LN, Wu ZH, Zhao JH, Feng NP. Evaluation of skin viability effect on ethosome and liposome mediated psoralen delivery via cell uptake. J Pharm Sci 2104;103:3120-6.
15. Kuchekar A, Pujari R, Kuchekar S, Dhole S. Psoriasis: a comprehensive review. Int J Pharm Life Sci 2011;2:857-77.
16. Paudel KS, Milewski M, Swadley CL, Brogden NK, Stinchcomb AL. Challenges and opportunities in dermal/transdermal delivery. Ther Delivery 2010;1:109-31.
17. Pradhan M, Singh D, Singh MR. Novel colloidal carriers for psoriasis: current issues, mechanistic insight and novel delivery approaches. J Controlled Release 2013;170:380-95.
18. Coope H, Mckenna DJ, Alexandroff AB. Long term safety of biologics in the treatment of psoriasis. Psoriasis: Targets Therapy 2013;4:1-9.
19. Cevc G, Blume G. Hydrocortisone and dexamethasone in very deformable drug carriers have increased biological potency, prolonged effect, and reduced therapeutic dosage. Biochim Biophys Acta 2004;1663:61-73.
20. Dixit CM, Akhil S, Mukundan S, Gupta S. Development and in vitro evaluation of nanolipid carrier of clobetasol propionate and promaxine hydrochloride for topical delivery. Int J Appl Pharm 2018;10:28-36.
21. Carlotti ME, Sapino S, Peira E, Gallarate M, Ugazio E. On the photodegradation of dithranol in different topical formulations: use of SLN to increase the stability of the drug. J Dispers Sci Technol 2009;30:1517-24.
22. Ryan C, Korman NJ, Gelfand JM, Lim HW, Elmets CA. Research gaps in psoriasis: opportunities for future studies. J Am Acad Dermatol 2014;70:146-67.
23. Hu FQ, Yuan H, Zhang HH, Fang M. Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int J Pharm 2002;239:121-8.
24. Hu FQ, Jiang SP, Du YZ. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf B 2005;45:167-73.
This work is licensed under a Creative Commons Attribution 4.0 International License.